Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence study of IBI3027 versus Dupixent in moderate-to-severe atopic dermatitis
ChiCTR2600132741Phase 3Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Trial Group (IBI3027) with Control Group (Dupixent) (2 arms). Primary endpoint: Proportion of participants achieving EASI-75 at Week 16. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
IBI3027dupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600132741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132741.